We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) announced that it has received a binding offer of approximately $2.1 billion from a private equity firm, Platinum Equity, for its LifeScan diabetes device unit. The LifeScan unit makes blood glucose monitoring products and generated revenues of $1.5 billion last year.
J&J stock has declined 3.8% this year so far, which compares unfavorably with a gain of 1.2% recorded by the industry.
J&J has time until Jun 15 to accept the offer, failing which it will expire. If J&J accepts the offer, the transaction is expected to close by the end of the year.
Sales in J&J’s Diabetes Care franchise declined 9.7% in 2017 to $1.6 billion due to price decline and competitive pressure.
J&J has been evaluating potential strategic options for its Diabetes Care Units specifically, LifeScan, Animas Corporation, and Calibra Medical since early last year. In fact, in October, J&J announced that it will close operations of its Animas Corporation diabetes care unit and exit its insulin pump business. Animas will stop manufacturing Animas Vibe and OneTouch Ping insulin pumps. J&J said that per a deal with medical device maker, Medtronic, Inc. (MDT - Free Report) , patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump.
AbbVie’s earnings per share estimates have moved up 14% for 2018 and almost 10% for 2019 in the last 60 days. Shares of the company have shot up 18.4% this year.
Pfizer’s earnings per share estimates have moved up 6.9% for 2018 and 5.9% for 2019 in the last 60 days. Share price of the company has increased 2.5% in the past year.
More Stock News: This Is Bigger than the iPhone
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit
Johnson & Johnson (JNJ - Free Report) announced that it has received a binding offer of approximately $2.1 billion from a private equity firm, Platinum Equity, for its LifeScan diabetes device unit. The LifeScan unit makes blood glucose monitoring products and generated revenues of $1.5 billion last year.
J&J stock has declined 3.8% this year so far, which compares unfavorably with a gain of 1.2% recorded by the industry.
J&J has time until Jun 15 to accept the offer, failing which it will expire. If J&J accepts the offer, the transaction is expected to close by the end of the year.
Sales in J&J’s Diabetes Care franchise declined 9.7% in 2017 to $1.6 billion due to price decline and competitive pressure.
J&J has been evaluating potential strategic options for its Diabetes Care Units specifically, LifeScan, Animas Corporation, and Calibra Medical since early last year. In fact, in October, J&J announced that it will close operations of its Animas Corporation diabetes care unit and exit its insulin pump business. Animas will stop manufacturing Animas Vibe and OneTouch Ping insulin pumps. J&J said that per a deal with medical device maker, Medtronic, Inc. (MDT - Free Report) , patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump.
J&J carries a Zacks Rank #3 (Hold). Better-ranked large-cap pharma stocks include AbbVie, Inc. (ABBV - Free Report) and Pfizer Inc. (PFE - Free Report) , both with a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie’s earnings per share estimates have moved up 14% for 2018 and almost 10% for 2019 in the last 60 days. Shares of the company have shot up 18.4% this year.
Pfizer’s earnings per share estimates have moved up 6.9% for 2018 and 5.9% for 2019 in the last 60 days. Share price of the company has increased 2.5% in the past year.
More Stock News: This Is Bigger than the iPhone
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>